Media Library

Migraine can have up to four distinct phases—premonitory (or prodrome), aura, headache and post-drome— and each of them has many potential symptoms.

Hospitalization provides an opportunity for physicians to optimize heart failure treatment to reduce the likelihood of hospital readmission and death, reduce the burden of hospitalizations, and improve outcomes for patients living with heart failure.

Novartis and AveXis combine, aiming to transform the care of SMA, the #1 genetic cause of infant mortality.

The factsheet “Strengthening our Global Health & Corporate Responsibility function” provides an overview of our Global Health & Corporate Responsibility governance, structure, strategic priorities and commitments.

The fact sheet “Building trust with society: our priorities” provides key highlights around 4 areas: pricing and access to medicines; global health challenges; ethical standards; and corporate responsibility.

The Novartis Access one-year report describes first results, early learnings and challenges from our first twelve months on the ground. It also includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

Since 2015, Novartis Access has worked to deliver treatments for chronic diseases in lower-income countries. Read our two-year report for an in-depth look at results, learnings and challenges on the ground so far. It includes external perspectives and country updates, showcasing the progress we have made as we roll out the program.

As a leading healthcare company, we have a responsibility to help people get access to the treatments they need, no matter where they live. Our CR Performance Report gives you all the facts on the progress we are making. It is issued at the same time as our Annual Report to provide readers with a more integrated view of Novartis.

10 years ago we launched the Healthy Family program, Novartis first social business model, to improve health via education, affordable products and health services. This report provides information on how the program has evolved since then. It includes external perspectives and country updates, showcasing the learnings and progress we have made over the years.

The Annual Report provides an overview of our strategy and reviews the performance of Novartis in 2017.

Our Annual Report 2018 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results.

MalaFA (Malaria Futures for Africa) is an opinion research study commissioned by Novartis to capture the views of African malaria experts in 15 sub-Saharan African countries – from government, the research community and NGOs – on progress and remaining challenges toward the 2030 global malaria goals. Study co-chairs are Dr Richard Kamwi, Ambassador, Elimination 8 (E8), and Professor Bob Snow, of the KEMRI-Wellcome Trust programme, Kenya and University of Oxford, United Kingdom.